Zoetis Inc (ZTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zoetis Inc (ZTS) has a cash flow conversion efficiency ratio of 0.174x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($938.00 Million) by net assets ($5.40 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check ZTS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Zoetis Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Zoetis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Zoetis Inc (ZTS) shareholders funds for net asset value and shareholders' equity analysis.
Zoetis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zoetis Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chroma ATE Inc
TW:2360
|
0.032x |
|
UNIV.MUSIC GRP.ADR/050
F:0VD0
|
N/A |
|
Aena SA
MC:AENA
|
0.095x |
|
Vodafone Group Plc
MX:VODN
|
0.104x |
|
Shaanxi Coal Industry Co Ltd
SHG:601225
|
0.097x |
|
Beijing-Shanghai High Speed Railway Co Ltd
SHG:601816
|
0.026x |
|
Swisscom AG
SW:SCMN
|
0.137x |
|
Hanwha Aerospace Co Ltd
KO:012450
|
-0.071x |
Annual Cash Flow Conversion Efficiency for Zoetis Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Zoetis Inc from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Zoetis Inc (ZTS) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.77 Billion | $2.95 Billion | 0.619x | +31.31% |
| 2023-12-31 | $4.99 Billion | $2.35 Billion | 0.471x | +8.57% |
| 2022-12-31 | $4.40 Billion | $1.91 Billion | 0.434x | -10.83% |
| 2021-12-31 | $4.54 Billion | $2.21 Billion | 0.487x | -13.57% |
| 2020-12-31 | $3.77 Billion | $2.13 Billion | 0.563x | -14.99% |
| 2019-12-31 | $2.71 Billion | $1.79 Billion | 0.663x | -19.09% |
| 2018-12-31 | $2.19 Billion | $1.79 Billion | 0.819x | +8.70% |
| 2017-12-31 | $1.79 Billion | $1.35 Billion | 0.754x | +58.44% |
| 2016-12-31 | $1.50 Billion | $713.00 Million | 0.476x | -21.85% |
| 2015-12-31 | $1.09 Billion | $664.00 Million | 0.609x | +29.99% |
| 2014-12-31 | $1.34 Billion | $626.00 Million | 0.468x | -33.86% |
| 2013-12-31 | $962.00 Million | $681.00 Million | 0.708x | +530.09% |
| 2012-12-31 | $4.04 Billion | $454.00 Million | 0.112x | -15.55% |
| 2011-12-31 | $3.74 Billion | $497.00 Million | 0.133x | +75.14% |
| 2010-12-31 | $3.34 Billion | $254.00 Million | 0.076x | -- |
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more